Cancer Therapy

BLP25 liposome vaccine phase IIB data in lung cancer published

Published in Cancer Weekly, October 25th, 2005

Biomira, Inc., (BIOM, BRA) announced that an article entitled, "Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non-Small Cell Lung Cancer" has been published in the September 2005 issue of the Journal of Clinical Oncology (JCO).

The primary author of the article is Charles Butts of the Cross Cancer Institute, the lead investigator for the phase 2b study.

The survival results previously released and now published indicated a 4.4 month longer median survival for patients randomized to the BLP25 Liposome Vaccine (L BLP25) arm (88 patients) compared to the Best Supportive Care (BSC) arm (83 patients).

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry